Loading…
Repligen Corporation is projected to rise to $140.34 by 2027, a +24% move from its current price of $113.17. RGEN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $110.32 | $113.22 | $116.19 | +0.04% |
| May 30 | $109.19 | $113.27 | $117.49 | +0.09% |
| May 31 | $108.34 | $113.32 | $118.52 | +0.13% |
| Jun 1 | $107.64 | $113.36 | $119.39 | +0.17% |
| Jun 2 | $107.03 | $113.41 | $120.18 | +0.21% |
| Jun 3 | $106.49 | $113.46 | $120.90 | +0.26% |
| Jun 4 | $105.99 | $113.51 | $121.56 | +0.30% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $105.99 | $113.51 | $121.56 | +0.30% |
| Week 2 | $103.33 | $113.85 | $125.44 | +0.60% |
| Week 3 | $101.41 | $114.20 | $128.59 | +0.91% |
| Week 4 | $99.87 | $114.54 | $131.37 | +1.21% |
| Week 5 | $98.56 | $114.88 | $133.91 | +1.51% |
| Week 6 | $97.42 | $115.23 | $136.29 | +1.82% |
| Week 7 | $96.41 | $115.58 | $138.56 | +2.13% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems.
The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands.
The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Repligen Corporation (RGEN) is a healthcare stock with a current price of $115.06 and a market cap of $6.49B, ranked 1157 in market listings. It sits in the Healthcare sector as a diversified provider of bioprocessing technologies and systems. The stock trades with a 30-day technical range of $96.10 to $137.76 and current indicators show sentiment as NEUTRAL, with a 14-day RSI of 50.
The 50-day simple moving average is $117.81 and the 200-day simple moving average is $137.73. Key support is $102.87 and resistance is $132.70. Forecasts for the price path extend well above the current level, with annualized projections showing a rising trajectory from a 2026 avg of $115.06 toward substantially higher targets through 2050, highlighting a bullish longer-term outlook despite near-term uncertainty.
A major floor 23.6% below — a decisive break under it would weaken the trend.
The nearest floor, 9.1% below — buyers have tended to step in here.
The nearest ceiling, 17.3% above — a clean break opens room to run.
A major ceiling 50.2% above — clearing it would confirm fresh momentum.
Key RGEN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RGEN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $113.71 | Sell | $113.07 | Buy |
| MA 10 | $109.45 | Buy | $112.70 | Buy |
| MA 20 | $114.61 | Sell | $114.27 | Sell |
| MA 50 | $117.79 | Sell | $119.42 | Sell |
| MA 100 | $131.42 | Sell | $126.85 | Sell |
| MA 200 | $137.75 | Sell | $133.14 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.79 | Neutral |
| Stoch RSI (14) | 61.52 | Neutral |
| CCI (20) | -17.39 | Neutral |
| Williams %R (14) | -56.28 | Info |
| MACD (12,26,9) | 0.45 | Buy |
| ROC (12) | -8.33 | Sell |
| Bollinger %B (20,2) | 0.45 | Neutral |
| Stochastic %K (14) | 43.72 | Neutral |
| TRIX (15) | -0.33 | Sell |
| Awesome (5,34) | -4.89 | Sell |
| Ultimate (7,14,28) | 64.72 | Neutral |
| Momentum (10) | -0.43 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 116.83 | Sell |
| ADX (14) | 14.95 | Neutral |
| ATR (14) | 2.71 | Info |
The 30-day technical picture is NEUTRAL. RSI(14) is 50, suggesting balanced momentum near the midpoint. The 50-day SMA is $117.81, while the 200-day SMA sits at $137.73, indicating the near-term average is hovering below the longer-term trend line.
In the near term, the price trades within a 30-day range of $96.10 to $137.76. Support is noted at $102.87 and resistance at $132.70, placing the current price of $115.06 within a buying and selling band that could trend toward the resistance level if momentum shifts.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $102.87 | $113.17 | $160.32 | 0% | Neutral | |
| $111.86 | $140.34 | $186.20 | +24% | Bullish | |
| $115.51 | $148.67 | $204.10 | +31% | Bullish | |
| $111.65 | $146.82 | $207.08 | +30% | Bullish | |
| $113.42 | $152.01 | $219.36 | +34% | Bullish | |
| $116.79 | $159.25 | $234.47 | +41% | Bullish | |
| $134.10 | $185.82 | $278.57 | +64% | Bullish | |
| $154.61 | $217.51 | $331.46 | +92% | Bullish | |
| $147.50 | $210.52 | $325.69 | +86% | Bullish | |
| $146.48 | $211.96 | $332.56 | +87% | Bullish | |
| $197.83 | $304.68 | $507.11 | +169% | Bullish | |
| $305.77 | $523.99 | $950.94 | +363% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $102.87 | $113.17 | $133.53 | +0.00% |
| June 2026 | $100.37 | $117.75 | $141.31 | +4.05% |
| July 2026 | $99.53 | $117.69 | $143.06 | -0.05% |
| August 2026 | $100.39 | $119.45 | $146.64 | +1.50% |
| September 2026 | $104.11 | $124.52 | $154.09 | +4.24% |
| October 2026 | $104.77 | $125.90 | $156.93 | +1.11% |
| November 2026 | $103.00 | $124.29 | $155.90 | -1.28% |
| December 2026 | $104.86 | $127.04 | $160.32 | +2.22% |
Click any year to see its month-by-month RGEN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The RGEN price prediction for 2026 points to an average of $113.17 (low $102.87, high $160.32) — a potential gain of 0% on today's $113.17. A consolidation phase looks the most probable path here.
In 2027, RGEN is projected to trade between $111.86 and $186.20, averaging $140.34 — a potential gain of +24% from today's $113.17. That is up +24% on the projected 2026 average. Momentum favours further upside here.
Repligen Corporation's 2028 outlook centres on $148.67, within a $115.51 to $204.10 range. That is up +6% on the projected 2027 average. That marks a +31% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, RGEN could reach as high as $207.08, with a base case around $146.82 and support toward $111.65 — roughly +30% from $113.17. Momentum favours further upside here.
Expect RGEN to range from $113.42 to $219.36 through 2030. The $152.01 average target implies a +34% move from current prices. That is up +4% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The RGEN price prediction for 2031 points to an average of $159.25 (low $116.79, high $234.47) — a potential gain of +41% on today's $113.17. Momentum favours further upside here.
In 2032, RGEN is projected to trade between $134.10 and $278.57, averaging $185.82 — a potential gain of +64% from today's $113.17. That is up +17% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Repligen Corporation's 2033 outlook centres on $217.51, within a $154.61 to $331.46 range. That is up +17% on the projected 2032 average. That marks a +92% change versus current levels. Momentum favours further upside here.
By 2034, RGEN could reach as high as $325.69, with a base case around $210.52 and support toward $147.50 — roughly +86% from $113.17. Buyers look set to stay in control over this stretch.
Expect RGEN to range from $146.48 to $332.56 through 2035. The $211.96 average target implies a +87% move from current prices. That is up +1% on the projected 2034 average. Momentum favours further upside here.
The RGEN price prediction for 2040 points to an average of $304.68 (low $197.83, high $507.11) — a potential gain of +169% on today's $113.17. Buyers look set to stay in control over this stretch.
In 2050, RGEN is projected to trade between $305.77 and $950.94, averaging $523.99 — a potential gain of +363% from today's $113.17. That is up +72% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in RGEN today (≈ 8.836264 RGEN) could be worth
$4,630.15
+$3,630.15 (+363%) by 2050 · US Dollar
Based on the average projected RGEN price of $523.99 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RGENwould be worth at today's price.
$1,000 invested in RGEN on May 27, 2025 (≈ 8.160601 RGEN) would be worth
$923.54
-$76.46 (-7.6%) today · 0.92× · US Dollar
Based on a RGEN entry price of $122.54 vs. today's $113.17.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $111.74 | $1,012.8 | +1.3% |
| 1 month ago | $118.29 | $956.72 | -4.3% |
| 3 months ago | $133.65 | $846.76 | -15.3% |
| 6 months ago | $171.02 | $661.74 | -33.8% |
| 1 year ago | $122.54 | $923.54 | -7.6% |
| All time (5.0y) ago | $172.75 | $655.11 | -34.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RGEN forecast.
Our base-case forecast reaches $230.00 around 2040.
Implied market cap at $230.00: $12.97B
The multi-year forecast shows a bullish trajectory with rising averages and meaningful upside across the horizon. For 2026, the min is $102.87, the avg is $115.06, and the max is $165.56, with ROI 0 and a NEUTRAL sentiment. In 2027 the avg rises to $143.11 with a max of $191.28 and a min of $113.45, yielding an ROI of 24.4 and a bullish outlook.
The 2028 forecast places the avg at $151.35 (max $209.62, min $116.78) with ROI 31.5 and a continued bullish stance, followed by 2029 with avg $149.51 (max $212.97, min $112.77) and ROI 29.9. By 2030 the avg is $152.69 (max $222.75, min $112.87) and ROI 32.7, with a bullish sentiment persisting into 2031 (avg $160.34, max $238.85, min $116.37, ROI 39.4). The 2032–2035 window shows strong upside (2032 avg $189.06, max $286.97, min $134.88; 2033 avg $219.81, max $339.39, min $154.31; 2034 avg $211.94, max $332.42, min $146.52; 2035 avg $214.25, max $340.97, min $145.95) with ROI ranging from 64.3 to 91.0.
Longer-term projections extend to 2040 (avg $306.02, max $517.80, min $195.00, ROI 166) and 2050 (avg $526.35, max $974.02, min $298.92, ROI 357.5), both of which carry a bullish sentiment. These figures should be viewed as estimates, not guarantees, and reflect potential upside under variant market conditions and business performance.
Tap a question to reveal the answer.
The 2030 forecast lists an avg of $152.69, with a min of $112.87 and a max of $222.75; the predicted ROI is 32.7 and the sentiment is BULLISH.
The forecast shows a bullish trajectory from 2027 onward, with rising averages and positive ROI (e.g., 2027 ROI 24.4, 2028 ROI 31.5, 2030 ROI 32.7, 2031 ROI 39.4). 2026 is neutral with ROI 0. These projections suggest upside under the stated conditions, but they are estimates and not guarantees.
Yes. The max forecast values exceed $300 by 2033 ($339.39 max) and continue higher, with 2040 max $517.80 and 2050 max $974.02.
Current price is $115.06 and market cap is $6.49B.
The 30-day range is $96.10 to $137.76 with support at $102.87 and resistance at $132.70. RSI(14) is 50, SMA(50) is $117.81, and SMA(200) is $137.73; market sentiment is NEUTRAL.
Repligen Corporation Community Discussion
0Share your Repligen Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.